Skip to Main Content
Table I.

Elevation of serum IFN-γ levels following IL-18 administration

TreatmentaIFN-γ ± SD (pg/ml)b,c
Before5th Day
Group I: HBSS <15.6 <15.6 
Group II: IL-18 <15.6 57.12 ± 64.9 
Group III: IL-12 <15.6 400.0 ± 577.5 
Group IV: IL-18 and IL-12 <15.6 17671.5 ± 107.1 
TreatmentaIFN-γ ± SD (pg/ml)b,c
Before5th Day
Group I: HBSS <15.6 <15.6 
Group II: IL-18 <15.6 57.12 ± 64.9 
Group III: IL-12 <15.6 400.0 ± 577.5 
Group IV: IL-18 and IL-12 <15.6 17671.5 ± 107.1 
a

Each group of C57BL/6 mice received 1.0 μg of IL-18 and/or 0.1 μg of IL-12 i.p. once daily on days 7–13 after the i.d. inoculation of MCA205 tumor cells.

b

Results represent mean ± SD of serum IFN-γ from three mice. Blood samples were collected 1 day before (Before) and on the 5th day (5th Day) following protein injection. Serum IFN-γ was assayed by ELISA.

c

IL-10 levels were only measured in HBSS and IL-18-treated animals and were <15.6 pg/ml, which was not changed by IL-18 treatment.

Close Modal

or Create an Account

Close Modal
Close Modal